Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01200394 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
NCT01200394 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 256 participants.
The verdict
NCT01200394, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
Study Summary
PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
Interventions
- DRUG Placebo
- DRUG PF-00489791
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01200394
The ClinicalTrials.gov registry entry for NCT01200394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01200394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01200394 about?
NCT01200394 is a clinical study titled "A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy". PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.
What is the current status of trial NCT01200394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2010-12. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01200394?
The interventions under investigation include: Placebo (DRUG), PF-00489791 (DRUG).
Who is sponsoring clinical trial NCT01200394?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.